A 58-year-old male patient has been diagnosed with hypertension. On examination, there is no existing cardiovascular disease, no hypertension mediated organ damage (HMOD) and the renal function is normal. He should be immediately started with pharmacological management if his blood pressure is more than—

Explanation

## Correct Answer: A. ≥160/100 mmHg This question tests the **2017 ACC/AHA and Indian hypertension management guidelines** for initiating pharmacological therapy in uncomplicated hypertension. The key discriminator is the **absence of HMOD (hypertension-mediated organ damage), cardiovascular disease, and normal renal function**—this patient is at **low-to-moderate risk**. According to the **2017 ACC/AHA guidelines** (adopted by Indian cardiologists) and **Indian Society of Hypertension (ISH) recommendations**, pharmacological treatment thresholds depend on **absolute cardiovascular risk stratification**: - **High-risk patients** (with HMOD, CVD, diabetes, CKD, or 10-year ASCVD risk ≥10%): start drugs at ≥130/80 mmHg - **Low-to-moderate risk patients** (no HMOD, no CVD, normal renal function): start drugs at **≥160/100 mmHg** (or ≥150/90 in some guidelines) This 58-year-old has **no organ damage, no CVD, and normal renal function**—he is **low-risk**. Therefore, **lifestyle modification alone** is recommended first, with pharmacotherapy initiated only if BP remains ≥160/100 mmHg after 3–6 months of lifestyle changes. The threshold of ≥160/100 mmHg aligns with **Indian guidelines** emphasizing a conservative approach in uncomplicated hypertension to avoid overtreatment and polypharmacy in low-risk populations. This reflects the **Indian clinical context** where many patients present late with advanced HMOD, making early identification of truly low-risk cases important for resource-appropriate management. ## Why the other options are wrong **B. ≥140/90 mmHg** — This is the **diagnostic threshold for hypertension** (JNC 8 and older guidelines), not the **treatment initiation threshold** in low-risk patients. The 2017 ACC/AHA guidelines raised the treatment threshold to ≥160/100 mmHg for low-risk individuals. NBE traps students who confuse 'diagnosis' with 'treatment initiation'—140/90 is when you label someone hypertensive, not when you start drugs in uncomplicated cases. **C. >130/80 mmHg** — This **130/80 threshold is reserved for high-risk patients** (those with HMOD, CVD, diabetes, or CKD). This patient has **none of these risk factors**—he is explicitly low-risk. Using 130/80 would lead to **unnecessary polypharmacy and overtreatment** in a low-risk population. This is a classic NBE trap: applying high-risk thresholds to low-risk patients. **D. >150/100 mmHg** — While 150/100 mmHg is closer to the correct threshold, it is **not the guideline-recommended cutoff** for low-risk uncomplicated hypertension. The correct threshold is **≥160/100 mmHg** (note: ≥, not >). This option may trap students who remember a vague 'high number' but lack precision in guideline thresholds. The distinction between 150 and 160 reflects the evidence-based risk-benefit analysis in low-risk cohorts. ## High-Yield Facts - **Low-risk hypertension (no HMOD, no CVD, normal renal function): pharmacotherapy threshold is ≥160/100 mmHg** per 2017 ACC/AHA and Indian guidelines. - **High-risk hypertension (HMOD, CVD, diabetes, CKD): pharmacotherapy threshold is ≥130/80 mmHg**—a lower, more aggressive target. - **140/90 mmHg is the diagnostic threshold** for hypertension, not the treatment threshold in low-risk patients. - **Lifestyle modification (DASH diet, salt restriction, weight loss, exercise) is first-line** for 3–6 months in low-risk uncomplicated hypertension before escalating to drugs. - **HMOD includes left ventricular hypertrophy, albuminuria, reduced eGFR, carotid intima-media thickening, and retinopathy**—absence of these keeps the patient in the low-risk category. ## Mnemonics ****HMOD = High-risk flag**** If **H**ypertension **M**ediated **O**rgan **D**amage is present → treat at ≥130/80. If absent → treat at ≥160/100. Presence of HMOD automatically escalates treatment intensity. ****'160 for low-risk, 130 for high-risk'**** Two-number rule: **160/100** is the threshold for uncomplicated (low-risk) hypertension; **130/80** is for complicated (high-risk) hypertension. The 30 mmHg difference reflects risk stratification. ## NBE Trap NBE pairs 'hypertension diagnosis' (140/90) with 'treatment initiation' to trap students who conflate diagnostic criteria with therapeutic thresholds. Additionally, NBE may use 130/80 to lure students who memorize high-risk thresholds without reading the case for risk factors (HMOD, CVD, renal disease). ## Clinical Pearl In Indian primary care and outpatient settings, many uncomplicated hypertensive patients are over-treated with multiple drugs despite low cardiovascular risk. This guideline emphasizes **watchful waiting with lifestyle modification** in truly low-risk cases, reducing unnecessary polypharmacy and improving medication adherence—a pragmatic approach for resource-limited Indian healthcare. _Reference: 2017 ACC/AHA Hypertension Guidelines; Indian Society of Hypertension (ISH) Consensus Statement on Hypertension Management; Harrison Ch. 247 (Hypertension)_